A detailed history of Texas Yale Capital Corp. transactions in Biogen Inc. stock. As of the latest transaction made, Texas Yale Capital Corp. holds 3,987 shares of BIIB stock, worth $629,547. This represents 0.03% of its overall portfolio holdings.

Number of Shares
3,987
Previous 3,987 -0.0%
Holding current value
$629,547
Previous $924,000 16.45%
% of portfolio
0.03%
Previous 0.04%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2019

Jul 24, 2019

SELL
$219.29 - $241.72 $874,309 - $963,737
-3,987 Reduced 50.0%
3,987 $932,000
Q1 2019

May 10, 2019

BUY
$216.71 - $338.96 $864,022 - $1.35 Million
3,987 Added 100.0%
7,974 $1.88 Million
Q3 2017

Nov 08, 2017

BUY
$281.15 - $329.69 $1.12 Million - $1.31 Million
3,987
3,987 $1.25 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Texas Yale Capital Corp. Portfolio

Follow Texas Yale Capital Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Texas Yale Capital Corp., based on Form 13F filings with the SEC.

News

Stay updated on Texas Yale Capital Corp. with notifications on news.